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Background: Time in therapeutic range (TTR) may be a quality indicator for anticoagulation. Previous studies have demonstrated that heart failure 
(HF) and other comorbidities are associated with poorer anticoagulation control; however, this association was not studied in a representative US 
population.
Objective: To determine the association between HF, other comorbidities, patient characteristics, and TTR among patients with nonvalvular atrial 
fibrillation (NVAF).
Methods: We analyzed longitudinal patient-level anticoagulation management records collected between 2006 and 2010 by decision support 
software, CoagClinic™. Adult patients with NVAF who used warfarin over 12 months with no gap >60 days between visits were identified. The 
Rosendaal method was used to calculate TTR, and TTR <55% was defined as “lower TTR”. CHADS2≥2 was defined as “higher CHADS2”. Logistic 
regression analyses were conducted to determine the association between comorbidities and TTR.
Results: 23,425 patients met the study criteria. The mean (±SD) age was 74.8±9.7 years, with 84.8% ≥65 years. The most common comorbidities 
were hypertension (41.7%), diabetes (24.1%), HF (11.7%), and stroke (11.1%). The mean (±SD) TTR was 67.3±14.4; 18.7% of patients had “lower 
TTR”. In multivariable analyses, using age, gender, hypertension, diabetes, stroke, and region as covariates, HF was associated with “lower TTR” 
[adjusted OR (95%CI) = 1.41 (1.28, 1.56); p<.001]. Diabetes [1.28 (1.19, 1.38); p<.001], and stroke [1.15 (1.04, 1.27); p<.001] were also 
associated with “lower TTR”. Compared to the Northeast, the West region was 34% more likely to be associated with “lower TTR” [1.39 (1.26, 1.54); 
p<.001]. In the second multivariable analyses, using gender, and region as covariates, “higher CHADS2” was associated with “lower TTR” [adjusted 
OR (95%CI) = 1.11 (1.04, 1.18); p<.001].
Conclusions: Common comorbidities that accompany NVAF are associated with “lower TTR”. HF was associated with the greatest likelihood of a 
“lower TTR”, followed by diabetes, then stroke. Anticoagulation control is more challenging for patients with these conditions. Novel agents offering a 
predictable dose-response may benefit these patients.
